Biomedical Bonding AB (BMB) is a leading Swedish MedTech company at the forefront of developing cutting-edge adhesives, composites, and surgical methodologies. With a strong focus on the fast-growing market of hard tissue repair, BMB aims to revolutionize bone restoration surgeries. Founded by Professor Michael Malkoch, BMB is a spinout company from the prestigious Royal Institute of Technology in Stockholm.

Leveraging over a decade of intensive academic research, BMB has created an innovative adhesive platform to address the existing challenges in bone fracture surgery and dental restorations. By introducing a unique technology platform based on a novel category of adhesive resin-composites, BMB prioritizes biocompatibility, tissue-friendliness, and high mechanical strength. This approach sets BMB apart and has attracted funding from notable organizations such as Vinnova and EU Horizon 2020.

Collaborating with renowned institutions including Karolinska Institute and AO Research Institute Davos, as well as leading hospitals, BMB is committed to commercializing its products. Their patient-personalized composite-based fixators, known as the Bonevolent™ platform, offer a breakthrough alternative to traditional implantable metal fixators. BMB's vision is to improve treatments and enhance the quality of life for patients.

In summary, Biomedical Bonding AB is a pioneering Swedish MedTech brand dedicated to developing revolutionary adhesives, composites, and surgical methodologies. With a focus on hard tissue repair, they are set to transform the field of bone restoration surgeries and dental restorations with their innovative approaches and unique technology platform